To develop a decisional tool to identify the most cost-effective process flowsheets for allogeneic cell therapies across a range of production scales. Materials & methods: A bioprocess economics and optimization tool was built to assess competing cell expansion and downstream processing (DSP) technologies. Results: Tangential flow filtration was generally more cost effective for the lower cells/lot achieved in planar technologies and fluidized bed centrifugation became the only feasible option for handling large bioreactor outputs. DSP bottlenecks were observed at large commercial lot sizes requiring multiple large bioreactors. The DSP contribution to the cost of goods/dose ranged between 20-55%, and 50-80% for planar and bioreactor flowsheets, respectively. Conclusion: This analysis can facilitate early decision-making during process development. . Advantages of allogeneic cell therapies include being sourced from a healthy donor, which makes it more possible to scale-up rather than scale-out and cryopreserve the cell-based product for short-term storage and multidosing [1]. Hence it is possible to envisage allogeneic therapies following a product-driven, off-the-shelf business model. Yet, several cell therapy products have experienced manufacturing challenges upon scale-up leading to processes with high cost of goods (COG) and high process variability [2] [3] [4] . This has triggered increasing interest in estimating manufacturing costs and identifying opportunities for cost reduction. Simaria et al. present a detailed process economics analysis for cell expansion that predicted dose-demand combinations when planar technologies would cease to be feasible, as well as target performance capabilities of microcarrier-based systems for the industry to be sustainable for high-demand, high-dose (10 9 cells/dose) scenarios [5] . The commercial feasibility of cell therapies for large commercial lot sizes (e.g., 10
Allogeneic stem cells are showing clinical promise in several therapeutic indications, with regional approvals for graft-versus-host disease (GvHD; Prochymal ® , Osiris) and osteoarthritis (Cartistem ® , Medipost). Advantages of allogeneic cell therapies include being sourced from a healthy donor, which makes it more possible to scale-up rather than scale-out and cryopreserve the cell-based product for short-term storage and multidosing [1] . Hence it is possible to envisage allogeneic therapies following a product-driven, off-the-shelf business model. Yet, several cell therapy products have experienced manufacturing challenges upon scale-up leading to processes with high cost of goods (COG) and high process variability [2] [3] [4] . This has triggered increasing interest in estimating manufacturing costs and identifying opportunities for cost reduction. Simaria et al. present a detailed process economics analysis for cell expansion that predicted dose-demand combinations when planar technologies would cease to be feasible, as well as target performance capabilities of microcarrier-based systems for the industry to be sustainable for high-demand, high-dose (10 9 cells/dose) scenarios [5] . The commercial feasibility of cell therapies for large commercial lot sizes (e.g., 10 12 cells/lot) will depend not only on the technology capabilities for expansion but also on commercially available technologies for downstream processing that are capable of handling this high cell load. This article presents a decisional tool to investigate the impact of commercial doses, demands and lot sizes on the cost-effectiveness of scalable, single-use downstream processing and fill finish technologies for cell therapies. Figure 1 illustrates a typical cell therapy process flowsheet for allogeneic cell therapies. Cell expansion is performed using either planar technologies such as T-flasks or multi-layer stacked vessels (e.g., Cell Some cell therapy manufacturing processes include downstream processing and fill finish technologies that are not amenable to scale-up such as benchtop centrifuges for volume reduction and manual filling in laminar air flow cabinets. However, this quickly There are a limited number of DSP technologies that have been purpose designed to meet the specific needs of allogeneic cell therapy manufacturing at large scale. These requirements include minimal processing time, achieving high concentration factors while preserving high cell viabilities, integrating volume reduction and washing to reduce impurity levels to <1 ppm [6] and providing a low-shear processing environment. Furthermore, technologies need to be closed, automated, scalable and employ single-use components; the latter of which has the added potential benefits of reducing turnaround time and cost of goods [7] .
Early downstream processing efforts focused on adapting technologies utilized within the blood product processing industry to use single-use components for washing and concentration of cell therapy products at a small scale. Examples include the COBE 2991 (Terumo BCT, CA, USA) operating via density gradient centrifugation or Elutra Cell separation systems (Terumo BCT) which operate in fluidized bed centrifugation mode. However, the scale of these systems is a limitation as less than a liter can be processed per cycle. Other commercially available, continuous centrifugation-based systems such as the Carr Centritech Cell II or Unifuge allow for larger process volumes but may not easily integrate the washing step [8] . At commercial scales, handling harvest volumes of 100-1000s l per lot, it is necessary to consider more scalable technologies for volume reduction and washing. Hence this work focused on DSP technologies which were not only single-use, closed and automated but also scalable and with which experience in the commercial cell therapy industry was already available. These options include tangential flow filtration (TFF) and fluidized bed centrifugation (FBC). TFF is most commonly used in the protein or antibody industry for concentration or buffer exchange, and can also be optimized to work for cell therapy processes. During TFF, recirculation of the feed across the membrane surface minimizes filter fouling and also allows washing to be achieved when operated in diafiltration mode. Lonza (MD, USA) has optimized the TFF process set-up and operating conditions for both VR and washing of therapeutic cells (PCT Publication number WO2011091248 A1 [9] ). The filter used is a hollow fiber filter. These filters generally possess a lower hold-up volume compared with flat sheet membrane cassettes and are available in ready-to-use presterilized formats by companies such as GE Healthcare [8] . Low shear, specifically a shear rate of less than 4000 s -1 (PCT publication number WO2011091248 A1 [9] ), in these systems can be achieved by optimizing key process parameters such as the recirculation flow rate. Real-time monitoring of transmembrane pressure is also enabled by the incorporation of single-use pressure sensors. Gamma-irradiated bags, filters and tubing in addition to aseptic connectors such as GE Healthcare's Readymate™ connections and sterile tube welding reduce the risk of contamination.
FBC systems, such as the kSep ® (KBI Biopharma, NC, USA), operate via counter-flow centrifugation, to provide a low shear environment for the cells. The opposing forces of fluid flow and centrifugal force result in the formation of a fluidized bed of cells, which allows for both volume reduction and washing, clearing residuals such as serum albumin from the media. These systems have a varying total single-use chamber capacity from 400 ml to 6 l [10] that can potentially handle 10-100s l from the expansion stage.
At small-scale, microcarrier beads are normally separated from cells by sieving post-trypsinization. At medium-to-large scale, systems to separate viable cells from microcarriers at larger volumes are under development. The difference in size and density between cells and microcarriers can be utilized for the separation of the latter using fluidized bed centrifugation such as kSep. Similarly, TFF using hollow fiber filters of the appropriate pore size can also be used for microcarrier removal. In addition, it would be advantageous to perform micro-
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Connect with peers and follow opinion leaders Join today www.RegMedNet.com Research Article Hassan, Simaria, Varadaraju, Gupta, Warren & Farid carrier removal and VR and cell washing using the same technology so as to minimize losses between steps. More recently, alternative technologies for microcarrier separation are being developed, which include Pall Solohill's cell separation bag containing a 70 μm screen and Thermoscientific's HyQ Harvestainer [11] .
Since allogeneic cell therapies are most commonly stored in cryovials and cryopreserved, a range of automated vial filling machine scales were also investigated in this study. Following thawing of the cryopreserved product, in the clinic, the therapeutic cells should have a minimum viability of 70% (preferably more than 85%), and a recovery of greater than 80% of viable cells [8] . A typical final product concentration is around 10 million cells/ml (the focused target of this study) [8] , with the majority of products in the 5 million cells/ml to 25 million cells/ml range, as required, for example, for aggravated rheumatoid arthritis or GvHD disease, respectively (clinical trials identifier: NCT01663116 [12] , and identifier NCT00823316 [13] , assuming administration of 4-20 ml and an average patient weight of 100 kg). Vial filling at scale is likely to be carried out via largescale automated fill lines such as the Crystal ® Px system from Aseptic Technologies. Cryo freezers for cell therapies allow for controlled-rate freezing and uniform freezing profiles, where cells are stored in the vapor phase of liquid nitrogen. This together with subsequent cold-chain management should enhance cell viability and quality for the product.
To date, published cost studies for cell therapy bioprocessing have focused solely on expansion options [5, 14] . On the downstream front, Pattasseril et al. discussed the process limitations of traditional VR technologies used for cell therapy processing, and the potential capabilities of more scalable technologies that are being adapted for cell therapies [8] . However, there are no detailed cost studies published on downstream processing decisions for cell therapies. In this article, an integrated decisional tool incorporating bioprocess economics and optimization for addressing cell therapy downstream processing challenges is described. This article builds on the decisional tool described in [5] to capture the mass balances, equipment sizing, process economics and optimization algorithms for both the expansion and downstream processing stages of cell therapy bioprocesses. It describes the extension of the tool to model the distinctive features of each of the downstream processing stages so as to determine their cost-effectiveness for both planar and microcarrier-based flowsheets. The effect of scale and level of demand on optimal DSP technologies are investigated, highlighting the current technology limits and identifying where improvements in technologies are required to cope with larger future likely demands. Step
Process parameter Value

Microcarrier removal
Step yield (%) 90
Number of microcarriers/g 4.6 × 10
5
Diameter of a single microcarrier (μm) 150
Number of operators/unit 2
Volume reduction
Step yield (%) 85
Maximum time (h) 4
Target final product concentration (in the vial; million cells/ml) 
Volume reduction with Tangential flow filtration
Largest Cy total from 14 and 15 set to Cy total 
Materials & methods
Tool description
The decisional tool described in [5] was further developed to address the challenge of identifying the most cost-effective downstream processing and fill finish technologies and their sizes for cell therapies across a range of doses, demands and lot sizes. The model was created in C# with the .NET framework (Microsoft1 Visual Studio 2010, Microsoft Corporation, WA, USA) linked to Microsoft ® Access (Microsoft ® Corporation, WA, USA). The DSP bioprocess economics model together with the input database was utilized to establish possible process flowsheets taking into account key process and technology-specific limitations, and calculations for resource consumption and equipment sizing. The flowsheets were then analyzed by the optimization algorithm ( Figure 2 ) to establish the optimal process, with output results established in the database. Key input parameters for DSP, were the number of cells and total volume postexpansion and trypsinization; these are highlighted in Table 1 . Once the optimal USP technology was fixed, the DSP cost of goods per dose (COG DSP /dose) was determined for a specific DSP flowsheet. For this analysis, the COG DSP /dose was determined by the sum of the annual direct operating costs (i.e., materials, labor and QC) and indirect costs (facility-dependent depreciation Volume reduction with fluidized bed centrifugation:
Microcarrier removal with fluidized bed centrifugation
Vial filling precryopreservation Table 2 ).
The overall optimization framework is summarized in Figure 2 . The key equations used in the model are summarized in Table 2 and the nomenclature is provided in the Supplementary Material (see online at www. futuremedicine.com/doi/full/10.2217/RME.15.29).
Case study setup
An industrially relevant case study was set up to investigate volume reduction (VR) and fill finish technologies for commercial allogeneic mesenchymal stromal cell (MSC) therapies. Volume reduction technologies investigated included tangential flow filtration of various filter and single-use set-up sizes, and fluidized bed centrifugation sizes of different total volume capacities. Supplementary Tables A1 & A2) , had varying vial filling capacities from 180 × 1 ml vials/h (referred to as Fill-A) to 10,800 × 1ml vials/h (denoted as Fill-D in this article). These tables were generated from literature sources and vendor communications, in addition to advice sought from industrial experts with respect to technology limits and process trade-offs. Examples of associated commercial names are in the footnotes or legends of Table 1 & Supplementary Table A1 . The tool was run for different scenarios to investigate the impact of different doses ranging from 10 6 to 10 9 cells/dose, annual demands of 1000-500,000 doses/year, and lot sizes (50-10,000 doses/lot), in order to identify optimal volume reduction and vial filling technologies at different doses, demands and lot size scenarios. Table 1, and  Supplementary Tables A1 & A2 highlight the key process and cost assumptions of the model. Key model constraints included a limit of one equipment unit for volume reduction and washing per lot. This is a typical constraint in the well-established biopharmaceutical industry due to validation concerns. This is particularly important for cell therapy where time for cell concentration can be limited to 4-8 h [8] to maintain cell viability. For some cell types, tighter or more relaxed time constraints may be required. Another key model constraint was to determine whether the target final concentration at the end of the flowsheet could be reached, taking into account minimum harvest volumes for the VR technology. The time allowed for formulation and completion of vial filling precryopreservation was set to 2 h [8] because of the limited time cells can spend in cryopreservation medium at room temperature. This 2-h time-limit assumes the use of DMSO as a cryopreservation buffer, but could differ if a different cryopreservation medium was used.
Results & discussion
Process limitations of downstream processing technologies for cell therapy Figure 3A shows the maximum cell output attainable for planar and nonplanar expansion technologies considered in this article, when considering the maximum number of units that can possibly be handled in a single lot. The ideal number of volume reduction (VR) units was set to 1, and this was dependent on several factors including maximum cell and volume capacity of the technology, target final concentration, time constraints for this process step, flux for TFF and operational flowrates for FBC. As each individual cell expansion unit such as T-flasks or Cell Factories produces a different number of cells per unit volume, the average, (0.36 billion cells/l) was used to evaluate TFF and FBC. As in [5] , the expansion technologies were given abbreviations such as 'L' to denote multilayer cell stacks or factories and 'cL' to denote compact multi-layer systems such as the Hyperstack (Corning, MA, USA). Figure 3A demonstrates that each expansion technology spans one log of performance in terms of billion cells per lot before being outperformed by a newer technology. For microcarrier-based singleuse bioreactors and the current performance in terms of cells per milliliter in culture (about 0.5 million cells/ml), two logs are attainable for single-use bioreactors (SUB) sizes spanning 20-2000 l; however, the maximum expected commercial lot size of 10 13 cells is not attainable, as described in [5] . Under the VR technology and process conditions described in Table 1 and  Supplementary Table A1 , which includes a target concentration of 10 million cells/ml and a constraint of 1 VR unit per lot, TFF can handle 3 billion cells (TFF-A with a 0.023 m 2 membrane and smaller associated process lines) to 152 billion cells per lot (TFF-F with a 1.15 m 2 membrane and larger associated process lines). Thus, for a target concentration of 10 million cells/ml, TFF is suitable for handling the maximum number of expansion units per lot for hollow fiber bioreactors, 9 cells/lot, respectively. To enable FBC use for the maximum number of T-flasks, multi-layer vessels and smaller compact multi-layer vessels, the target final concentration would have to be lowered for FBC-A [1ch] to less than 10 million cells/ml, and for the maximum number of automated multi-layer and compact multi-layer vessels, and the pooled load of eight SUBs, FBC-B [6ch] can be used but more than one would be required per lot.
For the dose, demand and lot size scenarios tested in the model, the number of 6 ml cryovials required per automated vial filling machine was plotted against cells per lot ( Figure 3B ). The number of cryovials required per optimal vial filling machine increased from 28 vials at 50 million cells per lot, to 2084 vials per vial filling machine at 250 billion cells per lot. The optimal vial filling machine capacities are plotted in the secondary axis of Figure 3B and have capabilities from 180 1 ml vials per hour (Fill-A) that are able to handle the lower cells per lot in the time constraint of 2 h, to 10,800 vials per hour for the largest automated fill machine (Fill-D).
Cost-effectiveness of downstream processing technologies for cell therapy Figure 4 addresses the overall optimal expansion, VR and vial filling technologies within the model's number of unit constraints for each step in the process. The expansion results are very similar to [5] where for expansion technologies the maximum number of planar expansion units that can be handled per lot is assumed to be 80 and the number of microcarrier-based SUBs is eight. The cell and volume outputs of optimal expansion technologies of Figure 4 are detailed in Table 1 . In this study, however, the overall DSP yield was assumed to be 68%, assuming an 85% VR yield and an 80% yield post thawing after cryopreservation. For processes including microcarrier-based SUBs, it was assumed that microcarrier removal resulted in a cell recovery of 90%, and hence the overall DSP yield was 61%. The optimal DSP technologies are based on optimal COG DSP /dose after finding the optimal USP technology based on COG USP /dose, in other words, for a fixed USP technology. This analysis considered typical commercial numbers of lots ranging from 10 to 200 lots per year. Each individual matrix cell shows the optimal technologies for a specific demand and lot size, in addition to the number of units required, indicated by square brackets. Facility depreciation was also taken into account in the indirect costs of this analysis, and so there is variation in optimal cell expansion technologies at each cells/lot compared to [5] . At lower lot sizes for a dose of 10 6 cells, the demand is met by smaller expansion systems ( Figure 4A ). In these cases, TFF-A is the only option for cell washing and VR due to the lower minimum harvest volume allowed. In these cases however, the final possible cells per milliliter is also lower, in other words, 0.3 -7 million cells/ml. For the smaller lot sizes and doses shown in Figure 4A there may be a possibility in achieving 10 million cells/ml if necessary instead of the lower targets theoretically achieved by the candidate technologies in our study using smaller systems used for concentrating lentiviral vectors, where it is possible to concentrate down to about 1 ml [15] . This would increase the scope of TFF even further. At a dose of 10 6 cells, a lot size of 2500 doses/lot, the optimal technologies that meet the maximum number of units constraints for each technology and can achieve the final desired 10 million cells/ml and have the overall combined total COG/dose is 9 cl-36 units or 6 L-40 units followed by FBC-A [1ch] and Fill-A because this is the only technology able to meet the target final concentration with one unit. Moving vertically down the matrix with increasing demand in doses/year, the difference in COG DSP /dose for alternate DSP technologies decreases. In situations where the COG/dose difference was less than 5%, the model determined that either technology was feasible and this is shown for example at a dose of 10 7 cells (Figure 4B ), a lot size of 500 doses/lot and a demand of 100,000 doses/year where both TFF-C and FBC-A [1ch] are equally competitive.
In general, moving horizontally across the matrices solution space, as lot size increases, larger capacity VR technologies are required, for example, larger area TFF filter membranes or a greater number of chambers for FBC or volume per chamber, all necessary for maintaining the one unit DSP constraint. At a dose of 10 7 cells per patient and a lot size of 10,000 doses/lot (Figure 4B ), the largest unit of TFF (TFF-F) is the optimal VR technology able to achieve the target final concentration with a single unit and this is followed by Fill-C. Figure 4C shows that at a dose of 10 8 cells and 2500 doses/lot, FBC-B is the clear winner as it is the only technology capable of meeting the number of units constraint of a single unit due to its larger cell and volume capacity. In our case study, filter areas of 0.023-1.15 m 2 were investigated since these hollow future science group Allogeneic cell therapy bioprocess economics: downstream processing decisions Research Article fiber systems are easily connected to sterile tubing and bags using GE Readymate TM sterile systems. However, filters of 2.6-11.3 m 2 are also available in the market and can be provided in irradiated, sterile format in a 'module, bag, tubing' or MBT (KrosFlo ® filters and KrosFlo ® MAX filters from Spectrum Labs). All TFF units tested in the study feature as optimal solutions with the exception of intermediates, TFF-B and TFF-E, only due to the incremental changes in cells per lot that we investigated in this study. For FBC-A either using one chamber to four chambers are optimal with cycling for up to two cycles possible in some cases, for example, at a dose of 10 8 cells, a demand of 50,000 doses per year and a lot size of 500 dose per lot. At a dose of 10 9 cells, ( Figure 4D ) and a lot size of 500 doses per lot, in other words, 0.5 × 10 11 cells per lot, although the optimal cell expansion technology are 3 × 1000 l or 5 × 500 l microcarrier-based SUBs, none of the VR technologies are capable of meeting the one unit constraint as it would be necessary to use 3 units 
TFF-A
Fill-A cL-36 [4] cL-36 [9] TFF-A of FBC-B with all six chambers to concentrate the pooled load from three SUBs within the 4-h time constraint, and this is represented by the light gray region in the matrix. Hence DSP bottlenecks are encountered before the USP bottleneck. The dark gray region at 10,000 doses per lot is due to both the cell expansion The optimal technology at each demand and dose is highlighted in italics in Figure 4 . At lower doses of number of cells per patient (e.g., 10 6 cells), the optimal technology is more greatly influenced by the number of lots per year, such that direct costs decrease with decreasing number of lots, or increasing lot size and indirect costs are constant as there is no change in equipment. At the other end of the dose spectrum (e.g., 10 9 cells), where the same DSP technology is used, indirect costs are similarly constant, but direct costs do not decrease in proportion with decreasing number of lots per year due to a need to process an increasing number of cells per lot causing an increasing direct cost for every lot.
FBC-A
Key cost drivers for downstream processing technologies for cell therapy Figure 5A is shown in COG DSP /year. As expected direct costs increase with dose output and indirect costs are fixed with increasing demand. These trends are similar for TFF and FBC. Figure 5B shows that direct COG DSP /dose for both technologies is constant. In contrast, the indirect COG DSP /dose decreases with demand, as these costs are spread over an increasing number of lots per year (at a fixed lot size), resulting in an overall decrease in COG DSP /dose due to economies of scale. As anticipated, the indirect COG DSP /dose represents a higher proportion of the total COG DSP /dose than the direct COG DSP /dose across all dose outputs, although the ratio of direct to indirect costs increases with demand for both technologies ( Figure 5C ). Figure 5D -F represent increasing cells per lot moving across a diagonal of the matrix at a dose of 10 7 cells, for a fixed number of lots per year of 50. Figure 5D & E illustrates that as cells per lot increases (by increasing lot size or scale of production), both direct and indirect costs increase, but the relative increase in indirect costs is much higher as larger equipment is required as scale of production increases. As the cells per lot increases, the scale of production increases and larger equipment are used to produce a greater amount of cells per lot and hence total COG DSP /dose overall and both direct and indirect COG DSP /dose decrease ( Figure 5E ). Thus, for a constant number of lots per year, the proportion of COG DSP /dose represented by indirect costs increases and those represented by direct costs decrease ( Figure 5F ). Figure 6A & B show a comparison of the cost breakdown for TFF and FBC for a fixed demand of 100,000 doses per year across different lot sizes (500 and 10,000 doses per lot) for a dose of 10 7 cells/patient. Throughout, depreciation and maintenance dominate as FCI is considered as 23.67 × the total equipment purchase cost, where 23.67 is the Lang factor previously established for disposable systems [16] . At 500 doses per lot, beyond depreciation, QC costs dominate, followed by material costs for TFF and FBC-A. Labor costs are the lowest contributor to overall costs in these cases. At 500 doses per lot, FBC-B cannot reach the target concentration factor of achieving 10 million cells per ml in the final vial due to its larger minimum harvest volume requirement brought about by its larger overall size and capacity, and hence it is not an option at this lot size. Overall, DSP technologies TFF-C with Fill-B and FBC-A [1ch] with Fill-B are optimal DSP technologies in terms of meeting the number of unit constraints and having the lowest COG DSP per dose for a fixed cell load of 18 l of 7.5 billion cells from 5 cl-120 units. The difference in COG DSP /dose between both options is only 6%. At 10,000 doses per lot, TFF-F followed by Fill-C is the optimal solution for COG DSP /dose ( Figure 6B ). At this lot size, depreciation is more significant due to the fact that there are fewer lots per year over which this depreciation can be spread. Since, FBC-A has a higher labor cost (1.7×) and a slightly higher depreciation and maintenance (1.2× greater) than TFF, TFF-F followed by Fill-C has a 21% lower COG DSP /dose than FBC-A [4ch, 2cy] which also requires two FBC units and is hence optimal. Unlike at 500 doses per lot, at 10,000 doses per lot, FBC-B can reach the target concentration factor and hence is an option however, with Fill-C the overall COG DSP /dose is 26% higher than TFF with Fill-C. The detailed direct cost breakdown for TFF at 500 doses per lot and 10,000 doses per lot are shown in Figure 6C & E. For FBC, Figure 6D & F show that similar to TFF, material costs are dominated by consumables rather than chemicals. On a per lot basis, QC costs dominate at 500 doses per lot whereas at 10,000 doses per lot, material costs are the main direct cost driver.
Improvements required in current DSP technologies for future demands Figure 7A & B analyzes debottlenecking strategies to address the gray region in Figure 4D where none of the candidate VR technologies are able to meet the number of unit constraints and assesses how the number of TFF-F and FBC-B units can be reduced to 1 unit. Figure 7A examines changing key VR parameters at a demand 50,000 doses per year and a lot size of 2500 doses per lot, and a dose of 10 9 cells/patient, to achieve the desired 1 DSP unit per lot constraint. For TFF, SUBs. For FBC processing this total load would require 9 FBC-B units. The left hand side of the graph has an increased process time constraint of 8 h, and explores the use of future rigs able to accommodate 3 filters with filter cartridge areas that are up to four times larger than the current maximum. For example, using three 4.6 m 2 membranes with this increased process time M-1000 [5] TFF-F Fill-D M-500 [5] FBC-B Fill-D [3] M-500 [5] FBC-B Fill-D [3] M-500 [5] FBC-B Fill-D [3] M-500 [5] FBC-B Fill-D [3] M-2000 [6] FBC-B Fill-D [2] M-2000 [6] FBC-B Fill-D [2] M-2000 [6] FBC-B Fill-D [2] M-1000 [5] TFF-F Fill-D M-1000 [5] TFF filter cartridges at this increased process time, and half the load processed per unit time by staggered upstream processing (USP) would also give rise to 1 unit. Using the same principle for FBC, a fivefold decrease in cell load to 1.8 l at the increased process time constraint of 8 h would also allow 1 DSP unit to be achieved. Figure 7B shows how 1 VR unit can be achieved in DSP for all gray regions in Figure 4D where the maximum number of SUBs per lot is not violated. This analysis shows that increasing the time allowed for this VR step to 8 h and/or staggering bioreactors allows 1 VR unit per lot to be achieved. At a dose of 10 9 cells and 500 doses per lot, a pooled load from five 500L bio- Figure 8B shows that COG USP : COG DSP split is 45:55 at 10 9 cells per lot to 80:20 at 10 11 cells per lot. Since upstream production is cheaper for MC-SUBs, Figure 8C shows that at 1 × 10 9 cells/lot COG USP : COG DSP split is 20:80, but this shifts to 50:50 at 10 11 cells/lot. The cost distribution between USP and DSP for microcarrier-SUB processes is similar to the traditional biopharmaceutical industry where for recombinant protein production DSP normally represents 50-80% of the total COG [17] . Our analysis thus, highlights that the COG USP : COG DSP ratio depends on both the upstream route (planar vs microcarrier-SUB) and the desired cells/ lot and hence these factors must be considered when identifying where to focus process development efforts.
Conclusion
Deviations from the process platform investigated in this paper may occur in some cases and impact the economics of processes, such as: addition of an irradiation step in DSP for MSCs in order to preserve their immunosuppressive potential and inhibit their clonogeneic capacity [18] ; the replacement of fetal bovine serum with human platelet lysate in cell culture and the subsequent impact on the DSP washing steps [19] , and alterations to cryopreservation and thawing logistics following reports suggesting that there is reduced immunodulatory function of cryopreserved MSCs upon thawing [19, 20] . Process economics analyses will help identify if these deviations have a significant impact on the overall economic feasibility of competing strategies.
Future perspective
Detailed process economics understanding as presented here provides visibility of the cost drivers, opportunities for cost reduction and allows the most promising strategies to be prioritized for further exploration. The upstream and downstream processing
Executive summary
A tool to identify the most cost-effective process flowsheets for allogeneic cell therapies
• A decisional tool to identify the most cost-effective process flowsheets for allogeneic cell therapies (mesenchymal stromal cells) across a range of production scales was developed.
• Bioprocess economics was integrated with optimization to assess the competitiveness of cell expansion technologies (i.e., planar or bioreactor) and single-use and scalable volume reduction technologies (VR).
Volume reduction technologies & downstream processing
• The tool predicted that tangential flow filtration was generally more cost effective for the lower cells per lot obtained in planar technologies and that fluidized bed centrifugation became the only feasible option for handling large bioreactor outputs.
• Commercial lot sizes greater than 500 billion cells per lot required multiple large bioreactors and was found to lead to VR bottlenecks.
• Debottlenecking strategies explored included staggering bioreactors and doubling the time constraint for VR.
• Downstream processing contribution to the COG per dose was found to be more significant at smaller scales with observed ranges of 20-55% using planar upstream technologies, and 50-80% using bioreactors.
Conclusion
• For lower cells per lot achieved in planar technologies, tangential flow filtration was the more cost-effective option.
• For higher cells per lot achieved in large single-use bioreactors, fluidized bed centrifugation became the only feasible option.
• Only bioreactor-based flowsheets coupled with either filtration or centrifugation would allow for a successful business model for high-dose scenarios.
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Research Article Hassan, Simaria, Varadaraju, Gupta, Warren & Farid bottlenecks identified highlight the technical innovation and optimization required to adapt existing technologies for cell therapies so as to bridge the gaps constraining large-scale production. The sector's progress is indicative that it will be able to move toward higher yielding, more robust and scalable manufacturing processes and that this will result in more cost-effective production of allogeneic cell therapies and hence feasible business models. Yet the benefits of early identification of cost effective and scalable manufacturing processes could be critical to achieving a sustainable business model. Companies face challenges handling commercial demands that require a switch in manufacturing technologies especially since cell characterization assays may make comparability difficult. Thus the cell therapy community and evolving development and regulatory pathway for mesenchymal stromal cells have an important role to play in the future economics for allogeneic cell therapy manufacturing. A future paper from the authors will present an analy sis of the consequences of process changes preand post-approval not only on cost of goods but also on the cost and time of drug development as well as the overall profitability over a drug's path to market. No writing assistance was utilized in the production of this manuscript.
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